| scholarly article | Q13442814 |
| P2093 | author name string | Ben K Seon | |
| Hilda Tsai | |||
| Hirofumi Toi | |||
| Masanori Tsujie | |||
| Shima Uneda | |||
| Tomoko Tsujie | |||
| Ken Shiozaki | |||
| P2860 | cites work | A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics | Q70536847 |
| A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues | Q70755356 | ||
| Barriers to drug delivery in solid tumors | Q72141985 | ||
| Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12 | Q73561535 | ||
| Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis | Q74462138 | ||
| Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies | Q74484401 | ||
| Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody | Q77161616 | ||
| Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells | Q77392041 | ||
| Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy | Q77555510 | ||
| Expression of endoglin (CD105) in tumor blood vessels | Q78016452 | ||
| Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies | Q78032793 | ||
| Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer | Q79347792 | ||
| Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells | Q24337230 | ||
| Defective angiogenesis in mice lacking endoglin | Q28144833 | ||
| Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide | Q28203483 | ||
| Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development | Q28585397 | ||
| Angiogenesis as a therapeutic target | Q29619525 | ||
| Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel | Q32046446 | ||
| Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells | Q33772145 | ||
| Recruiting dendritic cells to improve antibody therapy of cancer | Q33772194 | ||
| Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. | Q34504134 | ||
| Regulatory T cells in cancer | Q34550248 | ||
| Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents | Q34603062 | ||
| Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides | Q35642602 | ||
| Immunotherapeutic uses of CpG oligodeoxynucleotides | Q35730784 | ||
| Design of vascular endothelium-specific drug-targeting strategies for the treatment of cancer | Q36180619 | ||
| Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses | Q36376333 | ||
| Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells | Q36376481 | ||
| Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies | Q36657134 | ||
| Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis | Q37340349 | ||
| Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. | Q37404033 | ||
| Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. | Q40224481 | ||
| IL-12: a key cytokine in immune regulation | Q41305640 | ||
| Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). | Q42828746 | ||
| Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome | Q43622808 | ||
| Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. | Q50626711 | ||
| Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. | Q51618784 | ||
| Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. | Q52532578 | ||
| Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. | Q52832826 | ||
| Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. | Q53647266 | ||
| Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line | Q68098157 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| antibody | Q79460 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 2266-2273 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice | |
| P478 | volume | 122 |
| Q39023017 | (89)Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy. |
| Q26827543 | A lesson for cancer research: placental microarray gene analysis in preeclampsia |
| Q39368829 | Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. |
| Q26775947 | Anti-angiogenic alternatives to VEGF blockade |
| Q35201283 | Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature |
| Q37672682 | Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling |
| Q41889215 | Effects of the combination of TRC105 and bevacizumab on endothelial cell biology |
| Q36510958 | Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer |
| Q38180309 | Endoglin for targeted cancer treatment |
| Q38074721 | Endoglin for tumor imaging and targeted cancer therapy. |
| Q34341837 | Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization |
| Q34540047 | Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies |
| Q40068276 | Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. |
| Q37804900 | Endoglin-Targeted Cancer Therapy |
| Q35158941 | Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105) |
| Q35536671 | Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects. |
| Q35291271 | In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis |
| Q33913556 | Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. |
| Q33957962 | Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? |
| Q34672107 | Multiple delivery of siRNA against endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth |
| Q41970114 | Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer. |
| Q35017120 | Positron emission tomography imaging of CD105 expression during tumor angiogenesis. |
| Q37599664 | Receptor-targeted anticancer therapy |
| Q35314203 | Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth |
| Q34170622 | Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis |
| Q37610628 | Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours |
| Q37775427 | The physiological role of endoglin in the cardiovascular system. |
| Q30582833 | The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells |
| Q39365796 | Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. |
| Q55385227 | Tumor angiogenesis and anti-angiogenic gene therapy for cancer. |
| Q35851032 | Tumor neoangiogenesis detection by confocal laser endomicroscopy and anti-CD105 antibody: Pilot study. |
| Q45886138 | Tumor radiosensitization by gene therapy against endoglin |
| Q38962280 | Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma |
Search more.